News
- Author:
- Mary Jo Dales
Publish date: June 6, 2019
Rechallenge resulted in the recurrence of a grade 2 or higher immune-related adverse event (irAE) in 55% of rechallenged patients, but no deaths oc...
News
- Author:
- Mary Jo Dales
Publish date: February 26, 2018
Abemaciclib plus an aromatase inhibitor was approved as initial endocrine-based therapy in women with HR-positive, HER2-negative metastatic breast ...
News
- Author:
- Mary Jo Dales
Publish date: February 17, 2018
News
- Author:
- Mary Jo Dales
Publish date: October 25, 2017
The findings beg the issue of why clinicians overrely on short-acting rather than recommended long-acting bronchodilators for maintenance treatment...
News
- Author:
- Mary Jo Dales
Publish date: September 23, 2017
Lomitapide's rare disorder target was portrayed as vague to extend its use to more patients, according to the FDA.
News
- Author:
- Mary Jo Dales
Publish date: April 7, 2017
The ipsogen JAK2 RGQ PCR Kit has been given marketing authorization by the Food and Drug Administration.
Article
- Author:
- Mary Jo Dales
Publish date: December 4, 2016
SAN DIEGO – Induction therapy with the investigational drug CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin, allowed...
Article
- Author:
- Mary Jo Dales
Publish date: November 11, 2016
Using platelet microcapsules to deliver factor VIII, a process that is expected to increase factor VIII efficacy and avoid the development of neutr...
Article
- Author:
- Mary Jo Dales
Publish date: November 9, 2016
CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin, allowed a higher proportion of patients over age 60 with secondary AML to...
Article
- Author:
- Mary Jo Dales
Publish date: October 26, 2016
Long-term supplemental oxygen had no benefit on multiple outcome measures in patients with stable COPD and resting or exercise-induced moderate des...
Article
- Author:
- Mary Jo Dales
Publish date: October 24, 2016
In-hospital mortality did not vary for patients who received transfusions of blood that had been stored for 2 weeks and for patients who got blood ...
Article
- Author:
- Mary Jo Dales
Publish date: October 13, 2016
Patients who have chronic lymphocytic leukemia and achieve minimal residual disease negativity have a high probability of long-term progression-fre...
Article
- Author:
- Mary Jo Dales
Publish date: October 13, 2016
CD49d was a strong predictor of overall survival in a cohort of 778 unselected patients with chronic lymphocytic leukemia.
News
- Author:
- Mary Jo Dales
Publish date: August 12, 2016
Key clinical point: Patients with multiple myeloma should be assessed for VTE risk and thromboprophylaxis on an ongoing basis throughout the disea...
News
- Author:
- Mary Jo Dales
Publish date: August 11, 2016
Key clinical point: Quality of-life measures were comparable for multiple myeloma patients whether they received panobinostat or placebo in combin...
